419
Participants
Start Date
December 14, 2015
Primary Completion Date
October 23, 2020
Study Completion Date
October 23, 2020
Nivolumab
Docetaxel/Paclitaxel
Taoyuan Clinical Site, Taoyuan District
Changhua Clinical Site, Changhua
Tainan Clinical Site, Tainan City
Kaohsiung Clinical Site, Kaohsiung City
Odense University Hospital, Odense C
Taipei Clinical Site, Taipei
Taipei Clinical Site, Taipei
Gyeonggi-do Clinical Site, Gyeonggi-do
Georgetown University Med Ctr, Washington D.C.
Fondazione Irccs Istituto Nazionale Tumori, Milan
Keelung Clinical Site, Keelung
HPG23, Bergamo
Duke Cancer Institute, Durham
Orlando Health, Inc, Orlando
Daejeon Clinical Site, Daejeon
Irccs Istituto Oncologico Veneto Iov, Padua
Vanderbilt-Ingram Cancer Ctr, Nashville
Taichung Clinical Site, Taichung
Daegu Clinical Site, Daegu
Daegu Clinical Site, Daegu
Ulsan Clinical Site, Ulsan
Busan Clinical Site, Busan
RWTH Aachen University, Aachen
University Of Mainz Medical Center, Mainz
Hwasun-Gun Clinical Site, Hwasun-Gun
Chiayi Clinical Site, Chiayi City
University Hospital Heidelberg, Heidelberg
The University Of Texas MD Anderson Cancer Center, Houston
Klinikum reechts der Isar, Technical University Munchen, Munich
Kaohsiung Clinical Site, Kaohsiung City
Kaohsiung Clinical Site, Kaohsiung City
Banner MD Anderson Cancer Center, Gilbert
Massachusetts General Hospital, Boston
Charite Campus Virchow Klinikum, Berlin
Universitatsklinikum Jena, Innere Medizin II, Jena
MVZ Mitte, Leipzig
Aichi Clinical Site, Nagoya
Aichi Clinical Site, Nagoya
Aomori Clinical Site, Hirosaki
Chiba Clinical Site, Kashiwa
Ehime Clinical Site, Matsuyama
Hokkaido Clinical Site, Sapporo
Hokkaido Clinical Site, Sapporo
Hyogo Clinical Site, Akashi
Hyogo Clinical Site, Kobe
Kanagawa Clinical Site, Isehara
Kanagawa Clinical Site, Kawasaki
Kanagawa Clinical Site, Yokohama
Kanagawa Clinical Site, Yokohama
Mie Clinical Site, Tsu
Miyagi Clinical Site, Sendai
Nagano Clinical Site, Saku
Niigata Clinical Site, Nigatake
Osaka Clinical Site, Sayama
Osaka Clinical Site, Suita
Osaka Clinical Site, Takatsuki
Saitama Clinical Site, Hidaka
Saitama Clinical Site, Kita-Adachi County
Shizuoka Clinical Site, Suntou County
Tochigi Clinical Site, Shimotsuke
Tokyo Clinical Site, Bunkyo-ku
Tokyo Clinical Site, Chuo-ku
Tokyo Clinical Site, Chuo-ku
Tokyo Clinical Site, Koto-ku
Tokyo Clinical Site, Meguro-ku
Tokyo Clinical Site, Minato-ku
Tokyo Clinical Site, Shinagawa-ku
Tokyo Clinical Site, Shinjuku-ku
Tokyo Clinical Site, Shinjuku-ku
Akita Clinical Site, Akita
Chiba Clinical Site, Chiba
Chiba Clinical Site, Chiba
Fukuoka Clinical Site, Fukuoka
Fukushima Clinical Site, Fukushima
Hiroshima Clinical Site, Hiroshima
Kagoshima Clinical Site, Kagoshima
Kumamoto Clinical Site, Kumamoto
Kyoto Clinical Site, Kyoto
Kyoto Clinical Site, Kyoto
Niigata Clinical Site, Niigata
Osaka Clinical Site, Osaka
Shizuoka Clinical Site, Shizuoka
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Seoul Clinical Site, Seoul
Velindre Cancer Centre, Cardiff
The Beatson West Of Scotland Cancer Centre, Glasgow
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Ono Pharmaceutical Co. Ltd
INDUSTRY